Overview

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg
Phase:
Phase 1
Details
Lead Sponsor:
EyePoint
EyePoint Pharmaceuticals, Inc.